Dr Fatima Cardoso, director of the Breast Cancer Unit at Champalimaud Cancer Centre in Lisbon, Portugal, is a leader in a global initiative [2] to improve the care and treatment of persons with ...
Regor Pharma, a Shanghai-Boston biotech, sold global rights to Genentech for two early-stage CDK inhibitors aimed at breast cancer. Kailera Therapeutics launched with a four-drug pipeline aimed at the ...
Dublin, April 07, 2026 (GLOBE NEWSWIRE)-- The "Purvalanol A (CDK Inhibitor) Market Report 2026" has been added to ResearchAndMarkets.com's offering. The Purvalanol A (CDK Inhibitor) market has ...
(RTTNews) - Regor Pharmaceuticals USA has entered into a definitive purchase agreement, under which Genentech, a member of the Roche Group, will acquire a portfolio of next-generation CDK inhibitors ...
– Filing acceptance based on Phase III data showing giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, ...
As clinicians celebrated results of the PALOMA-2 study at ASCO Annual Meeting in 2016, Gabe S. Sonke, MD, PhD, had a question ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The current PI3K 3C inhibitors in use in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results